Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
- Interim analysis shows improved safety and efficacy of NGC-Cap over capecitabine
- Lower doses of NGC-Cap result in 5-FU exposure up to 10 times greater than capecitabine with similar side effect profiles
- FDA confirms NGC-Cap as a new chemical entity, suggesting higher efficacy and better safety profile
- None.
Insights
Processa Pharmaceuticals' announcement regarding the interim analysis of NGC-Cap Phase 1b study has significant implications for the company's valuation and the broader oncology market. The data suggest that NGC-Cap, a new formulation of capecitabine, offers a potentially enhanced safety and efficacy profile, which is critical in oncology therapeutics. Notably, the lower dosage requirement and the reduced side effects associated with NGC-Cap may position it as a preferable alternative to existing treatments. The FDA's recognition of NGC-Cap as a New Chemical Entity could afford the company market exclusivity benefits, which would protect its competitive position upon successful completion of clinical trials and approval.
For investors, the development represents a milestone that could influence the company's stock performance. The potential for NGC-Cap to capture market share in the chemotherapeutic space is considerable, given the emphasis on reducing toxicity while maintaining or improving efficacy in cancer treatments. The prospect of entering a Phase 2 trial indicates progression in the drug's development lifecycle, which is a critical factor in assessing the investment risk profile. However, it is important to note that the drug is still in early stages of development and further studies are required to confirm these interim results. The long-term impact will depend on the outcomes of subsequent trials, regulatory approval processes and the ability to commercialize effectively.
The clinical data presented by Processa Pharmaceuticals on NGC-Cap's improved safety profile, despite higher 5-FU exposure, is a promising development in the field of oncology. It suggests that NGC-Cap could lead to better patient outcomes due to its unique metabolic pathway that limits the production of FBAL, a catabolite known to cause significant side effects such as hand-foot syndrome. The ability to achieve higher efficacy with lower doses could translate into improved quality of life for patients and potentially alter the standard of care in cancer treatment regimens. This could have a profound impact on patient compliance and overall treatment success rates. As an oncology doctor, the balance between efficacy and safety is paramount and NGC-Cap's profile could represent a meaningful advancement in this respect.
It is also noteworthy that the interim analysis indicates a similar anabolite side effect profile to FDA-approved capecitabine, which may ease the transition for patients from existing treatments. The FDA's guidance on dosing regimens is indicative of a collaborative regulatory approach that could facilitate the drug's development. Nonetheless, the medical community will await the results of Phase 2 trials with anticipation, as these will provide more robust data on NGC-Cap's potential benefits and limitations.
Processa Pharmaceuticals' interim Phase 1b findings for NGC-Cap, coupled with the FDA's acknowledgment of the drug as a New Chemical Entity, could have a substantial impact on the company's market positioning. The pharmaceutical market places a premium on drugs that can offer improved efficacy with fewer side effects, a profile that NGC-Cap appears to fulfill. This could enhance the company's marketability and lead to strategic partnerships or funding opportunities to further drug development. The anticipated Phase 2 trials will be closely monitored by market analysts, as the results could significantly affect the company's future revenue streams and market capitalization.
The upcoming Fireside Chat is an important event for current and potential investors, as it will provide insights into the company's corporate strategy and the NGC platform's role within it. While the chat itself is not expected to directly impact the stock market, the information disclosed could influence investor sentiment and speculative activity. The registration link and the archiving of the chat content suggest transparency and accessibility, which are positively regarded in investor relations.
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU
Interim analysis of the NGC-Cap Phase 1b data shows improved safety, even with 5-FU exposure much greater than that from capecitabine
Company to conduct Fireside Chat at 4:30PM ET on December 20, 2023
HANOVER, MD, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the safety and efficacy for more cancer patients, provides an interim analysis from its Phase 1b study of its Next Generation Capecitabine (NGC-Cap).
“These initial data provide our first confirmatory clinical evidence that NGC-Cap is metabolized differently than capecitabine and, as a result, may offer significant improvements in safety and efficacy over capecitabine, a commonly used chemotherapeutic agent across multiple cancer indications. We are encouraged to be near completion of the Phase 1b trial as we make preparations for a subsequent Phase 2 trial with NGC-Cap,” said David Young, Pharm.D., Ph.D., President of Research and Development at Processa.
Thus far in the Phase 1b study, patients have received doses of NGC-Cap ranging from 75 mg once a day to 225 mg twice a day, significantly less than the 1,600 mg to 2,500 mg twice a day dose administered for FDA-approved capecitabine. More importantly, these much lower doses for NGC-Cap result in 5-FU (5-fluorouracil, the main metabolite of capecitabine that further metabolizes into desirable cancer-killing molecules called anabolites and undesirable molecules called catabolites that cause unwanted side effects) exposure up to 10 times greater than the higher FDA-approved capecitabine doses due to NGC-Cap’s unique metabolic pathway. One would anticipate that the much greater 5-FU exposure would result in greater and/or more severe side effects when, in fact, the side effect profile for 5-FU exposures from NGC-Cap had a similar anabolite side effect profile to FDA-approved capecitabine.
In addition, the side effects associated with FBAL (fluoro-beta-alanine, the primary catabolite formed from the metabolism of 5-FU), such as hand-foot syndrome, that can lead to capecitabine intolerance, were almost non-existent, likely because FBAL exposure was approximately
Important to FDA’s request that we evaluate multiple dosage regimens to determine an Optimal Dosage Regimen, the interim analysis also shows that an improvement in the side effect profile was observed at a 5-FU NGC-Cap exposure of 5-6 times greater than FDA-approved capecitabine.
“We are very encouraged with the interim results from the Phase 1b trial.” added Dr. Young. “We also appreciate our recent interactions with FDA and their guidance on the future development of NGC-Cap, including determining the dosing regimens that will provide the best safety and efficacy profile for patients receiving NGC-Cap across many types of cancers. In addition, it is gratifying to receive confirmation from the FDA on NGC-Cap’s status as a new chemical entity, which may provide additional commercial advantages.”
These data confirm that the metabolic pathways that regulate how NGC-Cap is processed in the body suggest NGC-Cap may offer higher efficacy at lower doses of the underlying capecitabine agent, while simultaneously offering a better safety profile from less production of the side-effect producing catabolite FBAL that causes many of the dose-limiting side effects from treatment with capecitabine alone. It is believed that NGC-Cap’s ability to inhibit the production of catabolites like FBAL is key to the success of NGC-Cap. Further clinical studies are needed to confirm these interim observations.
The Company will conduct a Fireside Chat on December 20, 2023 at 4:30PM ET to discuss these data in further detail and lay out the Company’s corporate strategy with regard to the NGC platform. Investors interested in listening may register early for the event at https://event.choruscall.com/mediaframe/webcast.html?webcastid=7RISI7Mv. This link will also connect listeners to the Fireside Chat when it goes live. Content from the Fireside Chat will be archived through June 20, 2024.
About Capecitabine Administered with PCS6422 (NGC-Cap)
NGC-Cap combines the administration of PCS6422, the Company’s irreversible dihydropyrimidine dehydrogenase (DPD) enzyme inhibitor, with the administration of low doses of the commonly used chemotherapy capecitabine.
Capecitabine is the oral form of 5-FU and, along with 5-FU, is among the most widely used chemotherapy drugs available, particularly for solid tumors. When metabolized (after oral ingestion), it becomes 5-FU in the body, which, in turn, metabolizes to molecules called anabolites that actively kill duplicating cells, such as cancer cells, and to molecules called catabolites that only cause side effects. The presence of the DPD enzyme plays an integral role in the undesirable conversion of 5-FU to catabolites.
PCS6422 is a uracil analog that irreversibly inhibits DPD. PCS6422 is neither toxic nor active as a single agent in animals at comparable dose levels. However, when administered in combination with capecitabine or 5-FU, PCS6422 decreases the metabolism of 5-FU to the catabolites that only cause side effects.
About Processa Pharmaceuticals, Inc.
Processa is a clinical stage pharmaceutical company focused on developing the Next Generation Chemotherapy (NGC) drugs to improve the safety and efficacy of cancer treatment. By combining Processa’s novel oncology pipeline with proven cancer-killing active molecules and the Processa Regulatory Science Approach as well as experience in defining Optimal Dosage Regimens for FDA approvals, Processa not only will be providing better therapy options to cancer patients but also increase the probability of FDA approval for its Next Generation Chemotherapy (NGC) drugs following an efficient path to approval. Processa’s NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of these FDA-approved drugs while maintaining the existing mechanisms of killing the cancer cells. The company’s approach to drug development is based on more than 30 years of drug development expertise to efficiently design and conduct clinical trials that demonstrate a positive benefit/risk relationship. The Processa team has a track record of obtaining over 30 approvals for indications across almost every division of FDA. Using its proven Regulatory Science Approach, the Processa Team has experience defining the Optimal Dosage Regimen using the principles of the FDA’s Project Optimus Oncology initiative. The advantages of Processa’s NGCs are expected to include fewer patients experiencing side effects that lead to dose discontinuation, more significant cancer response and a greater number of patients -- in excess of 200,000 for each NGC drug -- who will benefit from each NGC drug. Currently under development are three next generation chemotherapy oncology treatments: Next Generation Capecitabine (PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers), Next Generation Gemcitabine (PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers), and Next Generation Irinotecan (PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers).
For more information, visit our website at www.processapharma.com.
Forward-Looking Statements
This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the documents filed by Processa Pharmaceuticals with the SEC, specifically the most recent reports on Forms 10-K and 10-Q, which identify important risk factors which could cause actual results to differ from those contained in the forward-looking statements.
For More Information:
Investors:
Bret Shapiro
CORE IR
ir@processapharma.com
Company Contact:
Patrick Lin
(925) 683-3218
plin@processapharma.com
FAQ
What is the company providing interim analysis for?
What did the interim analysis reveal about the safety and efficacy of NGC-Cap?
What did the FDA confirm about NGC-Cap?
When is the Fireside Chat scheduled, and what will it discuss?
Where can investors register for the Fireside Chat?
